1.RNA spliceosomal mutations in myeloid neoplasms.
Xiang-chou YANG ; Su-jiang ZHANG ; Hong-xia QIU
Chinese Journal of Hematology 2013;34(6):555-557
Hematologic Neoplasms
;
genetics
;
Humans
;
Mutation
;
RNA
;
genetics
;
RNA Splicing
;
Spliceosomes
;
genetics
2.Detection of serum neopterin in patients with hemophagocytic lymphohistiocytosis and its significance.
Wei-Feng CHEN ; Ji XU ; Hong-Xia QIU ; Xiang-Chou YANG ; Wei ZHANG ; Su-Jiang ZHANG ; Xiao-Yan ZHANG ; Jian-Yong LI
Journal of Experimental Hematology 2013;21(2):465-468
This study was aimed to detect the peripheral blood serum neopterin (Npt) level in the patients with hemophagocytic lymphohistiocytosis (HLH) and to explore its significance in HLH. The enzyme-linked immunosorbent assay (ELISA) was applied to detect the serum Npt level and sCD25 level in 20 HLH patients before and after treatment and 15 healthy controls. The results indicated that the serum Npt and sCD25 levels in HLH patients were significantly higher than those in healthy controls (P < 0.0001). The serum Npt and sCD25 levels in the HLH group decreased significantly after treatment, respectively (P < 0.0001). The correlation analysis of Npt with sCD25 before and after treatment showed that they had significant correlation (r = 0.81, P < 0.05 before treatment; r = 0.65, P < 0.05 after treatment). Meanwhile, the level of serum Npt and ferritin had a significant correlation in newly diagnosed HLH patients (r = 0.55, P < 0.05). It is concluded that the serum Npt may play an important role in the HLH pathogenesis, the enhancement of Npt levels has an important significance for diagnosis and evaluation for HLH.
Adolescent
;
Adult
;
Aged
;
Case-Control Studies
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Lymphohistiocytosis, Hemophagocytic
;
blood
;
diagnosis
;
Male
;
Middle Aged
;
Neopterin
;
blood
;
Young Adult
3.Anti-human 4-1BBL monoclonal antibody stimulates the nuclear translocation of NF-κB and the co-location of 4-1BBL/CD28 isoform in U937 cells.
Wei ZHANG ; Hong-Xia QIU ; Tian TIAN ; Wei-Feng CHEN ; Ju-Juan WANG ; Xiang-Chou YANG ; Ji XU ; Li-Min DUAN
Journal of Experimental Hematology 2013;21(5):1121-1125
This study was purposed to investigate the molecular mechanism of 4-1BBL reverse signals in the human acute monocytic leukemia cell line of U937. The U937 cell line was used as target cells, and stimulated by the mouse anti-human 4-1BBL monoclonal antibody 1F1. The nuclear translocation of NF-κB and the co-location of 4-1BBL and CD28i molecules in U937 cells were observed with confocal laser scanning microscopy. The protein and m-RNA expression levels of 4-1BBL and CD28i were detected by flow cytometry and RT-PCR respectively. The results showed that the significant nuclear translocation of NF-κB and co-localization of 4-1BBL and CD28i on membrane of U937 cells appeared after being stimulated by mAb1F1. It is concluded that the 4-1BBL reverse signals transduction mediating the growth of U937 cells relates with the nuclear translocation of NF-κB. CD28i may be involved in intracellular 4-1BBL reverse signaling pathways.
4-1BB Ligand
;
immunology
;
metabolism
;
Antibodies, Monoclonal
;
pharmacology
;
CD28 Antigens
;
metabolism
;
Coculture Techniques
;
Humans
;
NF-kappa B
;
genetics
;
Signal Transduction
;
U937 Cells
4.SRSF2 mutation in patients with chronic myelomonocytic leukemia.
Xiang-chou YANG ; Su-jiang ZHANG ; Chun QIAO ; Rui GUO ; Hong-xia QIU ; Jian-Yong LI
Chinese Journal of Hematology 2013;34(12):1024-1027
OBJECTIVETo investigate SRSF2 mutations in patients with chronic myelomonocytic leukemia (CMML) and the clinical characteristics of patients with SRSF2 mutants.
METHODSIn this study, the frequency of SRSF2 mutation in a cohort of 20 patients with CMML was detected by polymerase chain reaction (PCR) followed by direct sequencing to couple with their clinical features.
RESULTSOf 20 patients, 4 patients were found harboring SRSF2 mutations, including 2 P95L, 1 P95H and 1 P95R point mutations. There were no significantly statistical differences in terms of their clinical characteristics between mutant and wild type group.
CONCLUSIONSRSF2 mutation was not frequently occurred in CMML patients and might associated with poor prognosis. It might be a practically diagnostic maker and therapeutic target in CMML.
Adult ; Aged ; DNA Mutational Analysis ; Female ; Genotype ; Humans ; Leukemia, Myelomonocytic, Chronic ; genetics ; Male ; Middle Aged ; Mutation ; Nuclear Proteins ; genetics ; Prognosis ; Ribonucleoproteins ; genetics ; Serine-Arginine Splicing Factors
5.Treatment of two chronic myeloid leukemia patients with V299L mutation by using nilotinib.
Xiang-Chou YANG ; Hong-Xia QIU ; Su-Jiang ZHANG ; Ju-Juan WANG ; Yuan OUYANG ; Liang-Qin PAN ; Chun QIAO ; Jian-Yong LI
Journal of Experimental Hematology 2014;22(3):698-702
This study was aimed to enhance clinical understanding the effect of nilotinib on CML patients with V299L mutation who were resistant to imatinib. Bone marrow specimens from 2 cases of CML with V299L mutation were collected before and after the treatment with nilotinib. ABL mutation was detected by nested reverse transcription polymerase chain reaction (PCR) followed by direct sequencing. The clinical characteristics of the two cases were analyzed. The results showed that both cases were resistant to imatinib presented V299L mutation. Out of them 1 case achieved complete haematological response (CHR) after treatment with nilotinib for 6 months and another case abstained obvious molecular response after using nilotinib for 7 month. V299L mutation of both cases was turned into negative after the treatment with nilotinib. It is concluded that the nilotinib can safely and effectively override tyrosine kinase inhibitor (TKI) resistance mediated by the V299L mutation. The safety and efficacy of nilotinib for treatment of CML patients with TKI resistance and V299L mutation are satisfactory.
Adult
;
Aged
;
Benzamides
;
pharmacology
;
Drug Resistance, Neoplasm
;
drug effects
;
genetics
;
Humans
;
Imatinib Mesylate
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
drug therapy
;
genetics
;
Male
;
Mutation
;
Piperazines
;
pharmacology
;
Pyrimidines
;
pharmacology
;
therapeutic use